Ultragenyx Reports Second Quarter 2017 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Ultragenyx Pharma (RARE) Tops Q2 EPS by 1c
July 27, 2017 4:45 PM EDTUltragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($1.72), $0.01 better than the analyst estimate of ($1.73).
Cash, cash equivalents, and investments were $457.5 million as of June 30, 2017.
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
... More